| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2023-02-10 | Versor Investments LP | ANTARES PHARMA, INC. | 0 | 0.0% | EDGAR |
| SC 13G | 2022-05-06 | Versor Investments LP | ANTARES PHARMA, INC. | 8,849,711 | 5.2% | EDGAR |
| SC 13D | 2022-05-02 | Magnetar Financial LLC | ANTARES PHARMA, INC. | 13,191,998 | 7.7% | EDGAR |
| SC 13G | 2022-02-14 | Rubric Capital Management LP | ANTARES PHARMA, INC. | 10,800,000 | 6.4% | EDGAR |
| SC 13G/A | 2022-02-01 | BlackRock Inc. | ANTARES PHARMA, INC. | 12,023,196 | 7.1% | EDGAR |
| SC 13G/A | 2021-01-29 | BlackRock Inc. | ANTARES PHARMA, INC. | 11,826,153 | 7.1% | EDGAR |
| SC 13G/A | 2020-02-14 | ARMISTICE CAPITAL, LLC | ANTARES PHARMA, INC. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2020-02-11 | UBS Group AG | ANTARES PHARMA, INC. | - | - | EDGAR |
| SC 13G/A | 2020-02-05 | BlackRock Inc. | ANTARES PHARMA, INC. | 11,472,832 | 7.0% | EDGAR |
| SC 13G/A | 2019-02-14 | ARMISTICE CAPITAL, LLC | ANTARES PHARMA, INC. | 10,300,000 | 6.1% | EDGAR |
| SC 13G | 2019-02-14 | UBS Group AG | ANTARES PHARMA, INC. | 13,137,018 | 8.3% | EDGAR |
| SC 13G/A | 2019-02-04 | BlackRock Inc. | ANTARES PHARMA, INC. | 10,234,202 | 6.5% | EDGAR |
| SC 13G | 2018-02-16 | ARMISTICE CAPITAL, LLC | ANTARES PHARMA, INC. | 10,000,000 | 6.4% | EDGAR |
| SC 13G/A | 2018-02-14 | ARMISTICE CAPITAL, LLC | ANTARES PHARMA, INC. | 7,600,000 | 4.8% | EDGAR |
| SC 13G/A | 2018-02-13 | Broadfin Capital, LLC | ANTARES PHARMA, INC. | 4,535,647 | 2.9% | EDGAR |
| SC 13G | 2018-02-01 | BlackRock Inc. | ANTARES PHARMA, INC. | 9,340,209 | 6.0% | EDGAR |
| SC 13G/A | 2017-02-14 | ARMISTICE CAPITAL, LLC | ANTARES PHARMA, INC. | 11,000,000 | 7.1% | EDGAR |
| SC 13G/A | 2017-02-13 | Broadfin Capital, LLC | ANTARES PHARMA, INC. | 12,971,093 | 8.4% | EDGAR |
| SC 13G/A | 2016-07-08 | BlackRock Inc. | ANTARES PHARMA, INC. | 2,873,056 | 1.9% | EDGAR |
| SC 13G/A | 2016-02-16 | ARMISTICE CAPITAL, LLC | ANTARES PHARMA, INC. | 13,240,000 | 8.6% | EDGAR |